Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeVantage Corporation filings document formal disclosures for a Nasdaq-listed health and wellness company that sells nutrigenomic supplements, skin and hair care products, energy drink mixes, and pet supplements through an independent Consultant model. Recent Form 8-K reports furnish quarterly operating results and describe revenue by region, earnings measures, capital allocation, and material corporate events.
Proxy and meeting filings cover board elections, advisory executive compensation votes, auditor ratification, incentive-plan matters, and final stockholder voting results. Other current reports address executive departures, officer appointments, board changes, transition agreements, and compensatory arrangements, alongside exhibit-based press releases tied to financial results and governance actions.
LifeVantage Corp (LFVN) director Michael A. Beindorff reported a sale of company stock in a Form 4 filing. On 11/19/2025, a trust for which he and his spouse serve as trustees sold 12,607 shares of LifeVantage common stock at a weighted average price of $6.4198 per share, with individual trades executed between $6.39 and $6.48. After this transaction, he reported beneficial ownership of 43,806 shares held by the trust, 35,389 shares held directly, 126 shares held by his spouse as custodian for minor children, and 5,500 shares held by his spouse.
LifeVantage Corporation filed a Form S-8 to register securities for issuance under the LifeVantage Corporation 2017 Long‑Term Incentive Plan. The registration becomes effective upon filing in accordance with Rule 462(a).
The filing incorporates by reference the company’s most recent Form 10‑K, Form 10‑Q, and certain Form 8‑K reports. Exhibits include a legal opinion on the validity of the securities, auditor and counsel consents, and the plan document. The company states standard Delaware-law indemnification provisions for directors and officers and notes the SEC’s position that indemnification for Securities Act liabilities is unenforceable.
LifeVantage identifies itself as an accelerated filer and a smaller reporting company.
LifeVantage Corporation reported final results from its fiscal 2026 annual meeting held on November 6, 2025. Quorum was achieved with 9,571,454 shares (75.41%) represented out of 12,691,009 outstanding as of the record date.
All seven director nominees were elected. Stockholders approved, on an advisory basis, executive compensation with 7,420,820 votes for. They ratified Deloitte & Touche LLP as independent auditor with 9,539,267 votes for. An amendment to the 2017 Long‑Term Incentive Plan was approved with 5,382,441 votes for.
LifeVantage (LFVN) reported an insider equity grant. A director acquired 13,531 shares of common stock on 11/06/2025, reflected at $7.76 per share, which the filing notes equals the weighted average closing price over the ten trading days ending the day before the grant.
The grant will vest in a single installment on November 6, 2026, subject to the director’s continuous service. Following this grant, the director beneficially owns 23,999 shares, held directly.
LifeVantage (LFVN) reported a routine insider equity grant. Director Cynthia Latham acquired 13,531 shares of common stock on 11/06/2025 under the company’s outside director compensation program. The grant vests in a single installment on November 6, 2026, contingent on continuous service. The reported price of $7.76 reflects the weighted average closing price over the ten trading days preceding the grant date. Following this grant, her beneficial ownership stands at 64,879 shares, held directly.
Lifevantage (LFVN) reported a director equity grant. Director Raymond B. Greer acquired 13,531 shares of common stock on 11/06/2025 under the outside director compensation program at a price equal to the $7.76 weighted average closing price over the ten trading days ending the day before the grant.
The award will vest in a single installment on 11/06/2026, contingent on continued service. Following the grant, Greer beneficially owns 112,819 shares, held directly.
LifeVantage (LFVN) director Michael A. Beindorff reported insider activity on Form 4. On 11/06/2025, he received 13,531 shares under the outside director compensation program, scheduled to vest on November 6, 2026; the price shown is $7.76, equal to the weighted average closing price over the prior ten trading days. On 11/07/2025, he sold 1,000 shares at $7.33 (direct) and 35,000 shares at a weighted average $6.9215 (indirect via trust), with a portion sold to cover taxes from a restricted stock vesting. Following these transactions, holdings include 35,389 shares direct, 56,413 shares indirect via trust, 126 shares held by spouse as custodian for minor children, and 5,500 shares held by spouse.
LifeVantage (LFVN) director Dayton Judd reported an equity award on a Form 4. On 11/06/2025, he was granted 13,531 shares of common stock under the company’s outside director compensation program. These shares will vest in a single installment on November 6, 2026.
The filing lists a price of $7.76, described as the weighted average closing price for the ten trading days ending the day before the grant date. Following the transaction, Judd beneficially owns 47,162 shares directly and 749,325 shares indirectly through Sudbury Capital Fund, LP.
LifeVantage (LFVN) reported a routine insider equity award. Director Darwin Lewis acquired 13,531 shares of common stock on 11/06/2025 under the company’s outside director compensation program. The price reported was $7.76, defined as the weighted average closing price over the ten trading days ending the day before the grant.
These shares will vest in a single installment on November 6, 2026, contingent on continuous service. Following the grant, Lewis beneficially owns 130,748 shares, held directly.
LifeVantage Corporation filed a current report to note that it issued a press release on November 4, 2025 announcing its financial results for the three months ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference for full details of the quarterly performance.
LifeVantage Corporation filed a current report to note that it issued a press release on November 4, 2025 announcing its financial results for the three months ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference for full details of the quarterly performance.